Patrick T. Bruck

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Anna Pavlova, Lydia Wunderle, Johannes Oldenburg et al. · Blood · 2007 · 249 citations · Full text

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

Wolfgang Bethge, Jolanta Dengler, M Bornhäuser et al. · Leukemia · 2012 · 228 citations

Hematological Malignancy, Transplantation, Medicine +9

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Michael Stadler, Martin Bornhäuser, Gesine Bug et al. · Blood · 2005 · 199 citations · Full text

CYP2R1 (vitamin D 25‐hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans

Elizabeth Ramos‐Lopez, Patrick T. Bruck, Thomas Jansen et al. · Diabetes/Metabolism Research and Reviews · 2007 · 163 citations

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

Wolf‐Karsten Hofmann, Martina Komor, Urban Scheuring et al. · PubMed · 2003 · 107 citations